In September 2024, a readout from a separate trial of rocatinlimab elicited mixed reactions from analysts, who found the ...

OMLYCLO® (omalizumab-igec) is the first and only omalizumab biosimilar approved by the FDA Regulatory approval for ...

An expert explained the importance of the FDA’s approval of Ensacove for patients with ALK-positive non-small cell lung ...

DURHAM, N.C., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable ...

Common adverse reactions include headache, diarrhea, and pyrexia, with contraindications for hypersensitivity to the active substance or excipients. With 2 new self-administration methods ...